RENAL: TNF-alpha Inhibitor for Improving Renal Dysfunction and Primary Graft Dysfunction After Lung Transplant

Part of paid clinical trials in Chicago, Illinois.

Sponsor
Northwestern University
Study ID
NCT05950724
Phase
EARLY_PHASE1
Status
Enrolling By Invitation

Conditions

  • Lung Transplant; Complications

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Etanercept Injection [Enbrel] — DRUG
    25 mg subcutaneous injection

Study Details

The purpose of this study is to assess whether TNFa antibody use before lung transplant can prevent kidney injury after lung transplant.

Key Dates

Start date
Sep 17, 2023
Status verified
Feb 2026
Primary completion
Dec 31, 2026
Completion
Dec 31, 2027

Study Design

Enrollment
20 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Arms

  • Experimental: Etanercept
    Participants receive one dose (25mg) Etanercept via subcutaneous injection just prior to lung transplant. Following transplant, participants receive standard lung transplant care.
  • No Intervention: Control
    Participants receive standard lung transplant care.

Primary Outcome Measure

Occurrence of kidney dysfunction immediately after lung transplant [ Time Frame: Immediately after lung transplant ]

Locations (1)

FacilityCityStateZIPSite coordinators
Northwestern UniversityChicagoIllinois60611-

Find similar trials in Chicago, IL

By research site
Northwestern University· Chicago, IL

Related Studies